ITGDF (Integral Diagnostics) 3-Year RORE % : -79.18% (As of Dec. 2025)


ITGDF Integral Diagnostics Ltd ITGDF
78 GF Score
Price $2.61
GF Value $3.60
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Integral Diagnostics 3-Year RORE %?

Integral Diagnostics ITGDF 78 3-Year RORE % is -79.18 as of Dec. 2025. GuruFocus rates ITGDF with a GF Score™ of 78/100 and a GF Value™ of $3.60 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Integral Diagnostics ranks worse than 91.09% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Integral Diagnostics's 3-Year RORE % for the quarter that ended in Dec. 2025 was -79.18%.

The industry rank for Integral Diagnostics's 3-Year RORE % or its related term are showing as below:

ITGDF's 3-Year RORE % is ranked worse than
91.09% of 202 companies
in the Medical Diagnostics & Research industry
Industry Median: -7.935 vs ITGDF: -79.18

Integral Diagnostics  (OTCPK:ITGDF) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Integral Diagnostics 3-Year RORE % Related Terms


Integral Diagnostics 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Integral Diagnostics's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Integral Diagnostics 3-Year RORE % Chart

Integral Diagnostics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.48 -27.13 -56.96 106.67 29.33

Integral Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 116.19 106.67 20.28 29.33 -79.18

ITGDF vs TMO, DHR, IDXX: 3-Year RORE % Comparison

For the Diagnostics & Research subindustry, Integral Diagnostics's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Integral Diagnostics 3-Year RORE % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Integral Diagnostics's 3-Year RORE % falls into.


ITGDF
78GF Score
Integral Diagnostics Ltd ITGDF
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Integral Diagnostics 3-Year RORE % Calculation

Integral Diagnostics's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( 0.027--0.167 )/( -0.124-0.121 )
=0.194/-0.245
=-79.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -79.18 mean?
Integral Diagnostics (ITGDF) has a 3-Year RORE % of -79.18 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Integral Diagnostics and its competitors. According to the industry distribution chart, Integral Diagnostics ranks #184 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 91.1%.
Is Integral Diagnostics' 3-Year RORE % too high?
Integral Diagnostics' current 3-Year RORE % is -79.18. Based on the distribution chart, Integral Diagnostics ranks #184 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Integral Diagnostics has a GF Score™ of 78/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #184 out of 202 companies for 3-Year RORE %. This places Integral Diagnostics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Integral Diagnostics and its competitors. Integral Diagnostics's current 3-Year RORE % is -79.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ITGDF) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.60, compared to a current price of $2.61 — trading 27.4% below its estimated fair value. The current 3-Year RORE % is -79.18. Integral Diagnostics' overall GF Score™ is 78/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Integral Diagnostics (ITGDF), the current 3-Year RORE % is -79.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integral Diagnostics (ITGDF) Overvalued in 2026?

Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued. The current stock price of $2.61 is trading 27.4% below its estimated GF Value™ of $3.60. GuruFocus considers Integral Diagnostics to be Significantly Overvalued.

Key valuation signals for ITGDF:

  • 3-Year RORE %: -79.18
  • GF Value™: $3.60 vs. price of $2.61 (27.4% below fair value)
  • GF Score™: 78/100 with 9 warning signs

No single metric tells the full story. See the ITGDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Integral Diagnostics Business Description

Other Exchanges IDX:Australia
Address 288 Victoria Parade, Level 2, Melbourne, VIC, AUS, 3002
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
78GF Score

Get the complete analysis for ITGDF

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.61
Price
$3.60
GF Value